All In Biotech

Free tool

FAERS Monitor: Beyfortus

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761328 or its brand name (Beyfortus, Nirsevimab-Alip). Reports on generic versions are filed under their own applications.

Reports

1,793

Serious

1,142

64% of reports

Hospitalization

762

Death reported

41

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective324
  • respiratory syncytial virus bronchiolitis302
  • respiratory syncytial virus infection251
  • incorrect dose administered234
  • bronchiolitis157
  • pyrexia114
  • cough112
  • extra dose administered84
  • expired product administered50
  • respiratory syncytial virus test positive50
  • dyspnoea46
  • wheezing44
  • apnoea42
  • rash39
  • product storage error38

Reports by year received

View as table
YearReports
2023143
2024450
2025772
2026428

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,366 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
respiratory syncytial virus bronchiolitisSignal3027387.36445.91,364,541
respiratory syncytial virus test positiveSignal50899.0676.940,833
bronchiolitisSignal157547.7469.981,342
respiratory syncytial virus infectionSignal251348.2309.884,080
apnoeaSignal4263.647.12,514
extra dose administeredSignal8424.419.81,859
expired product administeredSignal5017.713.4770
incorrect dose administeredSignal23412.010.72,380
wheezingSignal448.76.5293
product storage errorSignal385.13.7121
coughSignal1124.73.9325
pyrexiaSignal1143.93.2243
drug ineffectiveSignal3242.92.6423
rash391.00.80
dyspnoea461.00.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.